AKT1 and neoplasm: This approach will aim to direct those women who may not benefit from platinum to alternative regimens, for instance immune checkpoint inhibitors for POLE mutated or mismatch repair‐deficient tumours,24, 25, 26 and hormonal therapy or PI3K‐AKT‐mTOR inhibitors for nonspecific molecular profile (NSMP) cancers.27